Understanding how immune cells interact with tumor cells at the edges of brain tumors
Official title: Mapping Immune Contexture and Crosstalk with Tumor Cells At GBM Margin
Funded at Icahn School of Medicine at Mount Sinai · NIH-10925355 · Data updated 2026-11-12
This study is looking at how certain immune cells around glioblastoma tumors interact with the cancer, hoping to find new ways to slow down the growth of this aggressive brain cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 9, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $666,772 |
| NIH project number | 5R01NS134159-02 |
| Project ID | NIH-10925355 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing surgical treatment.
✕Less likely to help
Patients with other types of brain tumors or those who are not undergoing surgical intervention for glioblastoma may not benefit from this research.
What this research studies
This research investigates the interactions between immune cells and tumor cells at the margins of glioblastoma (GBM), a highly aggressive brain cancer. The study focuses on tumor-associated myeloid cells, particularly microglia, which are immune cells that gather at the edges of GBM tumors. By exploring how these immune cells contribute to tumor growth and invasion, the research aims to identify potential therapeutic targets that could slow down the progression of GBM. The approach includes manipulating specific signaling pathways to disrupt the supportive environment that allows tumors to thrive.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the recurrence of glioblastoma after surgery.
How similar studies have gone: Previous research has shown promising results in targeting immune cell interactions in tumors, suggesting that this approach could be effective.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Zou, Hongyan Jenny — Icahn School of Medicine at Mount Sinai
- Study coordinator: Zou, Hongyan Jenny
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.